会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明授权
    • Prostaglandin derivatives
    • 前列腺素衍生物
    • US06613932B1
    • 2003-09-02
    • US10070752
    • 2002-03-11
    • Fumie SatoTohru TanamiHideo TanakaNaoya OnoMakoto YagiHitomi Hirano
    • Fumie SatoTohru TanamiHideo TanakaNaoya OnoMakoto YagiHitomi Hirano
    • C07C6974
    • C07C405/00
    • A prostaglandin derivative represented by the formula: [wherein X is CH2, O or S(O)q1, Y is an ethylene group, a vinylene group, an ethynylene group, O(CH2)t1 or S(O)q2(CH2)t1, Z is an ethylene group, a vinylene group or an ethynylene group, R1 is a hydrogen atom, a C1-10 alkyl group or a C3-10 cycloalkyl group, R2 is a C1-10 alkyl group, a C2-10 alkenyl group, a C2-10 alkynyl group, a C3-10 cycloalkyl group, a C1-5 alkyl-C3-10 cycloalkyl group, a C3-10 cycloalkyl-C1-5 alkyl group, a hydroxy-C1-5 alkyl group, a halogeno-C1-5 alkyl group, a C1-5 alkoxy-C1-5 alkyl group, a C2-4 alkoxycarbonyl-C1-5 alkyl group, a carboxyl-C1-5 alkyl group, a cyano-C1-5 alkyl group, a C1-5 alkyl group substituted with a group represented by the formula: —NR7R8, an acyl group, a group represented by the formula: —(CH2)t2CH(NH2)COOR9, etc., and R3 is a hydrogen atom, a C1-10 alkyl group, etc.], a pharmaceutically acceptable salt thereof or a hydrate thereof. Novel prostaglandin derivatives of the present invention have an excellent action in inhibiting the growth of vascular smooth muscle, and are useful as drugs for prevention or treatment of the restenosis after PTCA, etc.
    • 由下式表示的前列腺素衍生物[其中X为CH 2,O或S(O)q1,Y为亚乙基,亚乙烯基,亚乙炔基,O(CH 2)t 1或S(O)q 2(CH 2) t1,Z是亚乙基,亚乙烯基或亚乙炔基,R1是氢原子,C1-10烷基或C3-10环烷基,R2是C1-10烷基,C2-10烯基 基团,C 2-10炔基,C 3-10环烷基,C 1-5烷基-C 3-10环烷基,C 3-10环烷基-C 1-5烷基,羟基-C 1-5烷基, 卤代C 1-5烷基,C 1-5烷氧基-C 1-5烷基,C 2-4烷氧基羰基-C 1-5烷基,羧基-C 1-5烷基,氰基-C 1-5烷基, 由下式表示的C1-5烷基:-NR7R8,酰基,由下式表示的基团: - (CH2)t2CH(NH2)COOR9等,R3为氢原子, C 1-10烷基等],其药学上可接受的盐或其水合物。本发明的新型前列腺素衍生物 在抑制血管平滑肌生长中具有优异的作用,可用作预防或治疗PTCA等后再狭窄的药物。
    • 2. 发明授权
    • Prostaglandin derivatives
    • 前列腺素衍生物
    • US06740772B1
    • 2004-05-25
    • US10070643
    • 2002-03-11
    • Fumie SatoTohru TanamiHideo TanakaNaoya OnoMakoto YagiHitomi Hirano
    • Fumie SatoTohru TanamiHideo TanakaNaoya OnoMakoto YagiHitomi Hirano
    • C07C17700
    • C07C405/00C07C405/0016
    • A prostaglandin derivative represented by the formula: wherein X is a halogen atom in the &agr;- or &bgr;-position, Y is an ethylene group, a vinylene group or an ethynylene group, A is a group represented by the formula: O(CH2)n, S(O)p(CH2)n, O(CH2)qO(CH2)r, O(CH2)qS(O)p(CH2)r, S(O)p(CH2)qS(O)p(CH2)r or S(O)p(CH2)qO(CH2)r (wherein n is an integer of 1 to 5, p is 0, 1 or 2, q is an integer of 1 to 3, and r is 0 or 1), R1 is a C3-10 cycloalkyl group, a C1-4 alkyl-C3-10 cycloalkyl group, a C3-10 cycloalkyl-C1-4 alkyl group, a C5-10 alkyl group, a C5-10 alkenyl group, a C5-10 alkynyl group or a bridged cyclic hydrocarbon group, R2 is a hydrogen atom, a C1-10 alkyl group or a C3-10 cycloalkyl group, and m is 0, 1 or 2], a pharmaceutically acceptable salt thereof or a hydrate thereof. The present invention is to provide novel PG derivatives having an excellent PGD2-like agonistic activity and a sleep-inducing action.
    • 由下式表示的前列腺素衍生物:其中X是α-位或β-位的卤素原子,Y是亚乙基,亚乙烯基或亚乙炔基,A是由下式表示的基团:O(CH 2) (O)p(CH2)q(O)p(CH2)q(O)p(CH2)q(O)p(CH2) CH 2)r或S(O)p(CH 2)q O(CH 2)r(其中n为1〜5的整数,p为0,1或2,q为1〜3的整数,r为0或1 ),R 1为C 3-10环烷基,C 1-4烷基-C 3-10环烷基,C 3-10环烷基-C 1-4烷基,C 5-10烷基,C 5-10烯基 基团,C5-10炔基或桥连环烃基,R 2是氢原子,C 1-10烷基或C 3-10环烷基,m是0,1或2],药学上可接受的 其盐或其水合物。本发明提供具有优异的PGD 2样激动活性和睡眠诱导作用的新型PG衍生物。
    • 3. 发明授权
    • Prostaglandin E1 derivatives
    • 前列腺素E1衍生物
    • US06455584B1
    • 2002-09-24
    • US09937782
    • 2002-01-04
    • Fumie SatoTohru TanamiHideo TanakaNaoya OnoMakoto YagiHitomi Hirano
    • Fumie SatoTohru TanamiHideo TanakaNaoya OnoMakoto YagiHitomi Hirano
    • C07C17700
    • C07C405/00A61K31/5575C07C405/0033
    • To provide a prostaglandin derivative represented by the formula: wherein A is an ethylene group, a vinylene group, an ethynylene group, O(CH2)q or S(O)r(CH2)q, R1 is a C3-10 cycloalkyl group, a C1-4 alkyl-C3-10 cycloalkyl group, a C3-10 cycloalkyl-C1-4 alkyl group, a C1-10 alkyl group, a C1-10 alkyl group substituted with hydroxyl group(s) or C1-4 alkoxy group(s), a C2-10 alkenyl group, a C2-10 alkenyl group substituted with hydroxyl group(s) or C1-4 alkoxy group(s), a C2-10 alkynyl group, a C2-10 alkynyl group substituted with hydroxyl group(s) or C1-4 alkoxy group(s) or a bridged cyclic hydrocarbon group, R2 is a hydrogen atom, a C1-10 alkyl group or a C3-10 cycloalkyl group, m is an integer of 1 to 5, n is an integer of 1 to 4, p is 0, 1 or 2, q is an integer of 1 to 5 and r is 0, 1 or 2; a pharmaceutically acceptable salt thereof or a hydrate thereof exhibit excellent action in inhibiting the growth of vascular smooth muscle and is useful as a drug for inhibition of restenosis after percutaneous transluminal coronary angioplasty.
    • 提供由下式表示的前列腺素衍生物:其中A是亚乙基,亚乙烯基,亚乙炔基,O(CH 2)q或S(O)r(CH 2)q,R 1是C 3-10环烷基, C 1-4烷基-C 3-10环烷基,C 3-10环烷基-C 1-4烷基,C 1-10烷基,被羟基或C 1-4烷氧基取代的C 1-10烷基 C2-10链烯基,被羟基或C1-4烷氧基取代的C2-10烯基,C2-10炔基,被羟基取代的C2-10炔基 基团或C 1-4烷氧基或桥连环烃基,R 2是氢原子,C 1-10烷基或C 3-10环烷基,m是1至5的整数,n 是1〜4的整数,p为0,1或2,q为1〜5的整数,r为0,1或2。 其药学上可接受的盐或其水合物在抑制血管平滑肌的生长中表现出优异的作用,并且可用作用于抑制经皮腔内冠状动脉成形术后再狭窄的药物。